Library — CHDR

Search

Filter

Evidence of NI-0101 pharmacological activity, an anti-TLR4 antibody, in a randomized phase I dose escalation study in healthy volunteers receiving LPS.

Monnet E, Lapeyre G, Poelgeest EV, Jacqmin P, Graaf K, Reijers J, Moerland M, Burggraaf J, Min C

Clinical pharmacology and therapeutics, 2018 Dec; 101(2):200-208

View publication
Injection site reactions after subcutaneous oligonucleotide therapy.

van Meer L, Moerland M, Gallagher J, van Doorn MB, Prens EP, Cohen AF, Rissmann R, Burggraaf J

British journal of clinical pharmacology, 2017 Sep; 82(2):340-51

View publication
IMO-8400, a toll-like receptor 7, 8, and 9 antagonist, demonstrates clinical activity in a phase 2a, randomized, placebo-controlled trial in patients with moderate-to-severe plaque psoriasis.

Balak DM, van Doorn MB, Arbeit RD, Rijneveld R, Klaassen E, Sullivan T, Brevard J, Thio HB, Prens EP, Burggraaf J, Rissmann R

Clinical immunology (Orlando, Fla.), 2016 Dec

View publication
Remarkable Pharmacokinetics of Monoclonal Antibodies: A Quest for an Explanation.

Reijers JA, Moerland M, Burggraaf J

Clinical pharmacokinetics, 2016 Dec

View publication
Clinical Evaluation of Humira(®) Biosimilar ONS-3010 in Healthy Volunteers: Focus on Pharmacokinetics and Pharmacodynamics.

Dillingh MR, Reijers JA, Malone KE, Burggraaf J, Bahrt K, Yamashita L, Rehrig C, Moerland M

Frontiers in immunology, 2016 Nov

View publication
Renal Effects of Antisense-Mediated Inhibition of SGLT2.

van Meer L, Moerland M, van Dongen M, Goulouze B, de Kam M, Klaassen E, Cohen A, Burggraaf J

The Journal of pharmacology and experimental therapeutics, 2016 Oct; 359(2):280-289

View publication
Use of population approach non-linear mixed effects models in the evaluation of biosimilarity of monoclonal antibodies.

Reijers JA, van Donge T, Schepers FM, Burggraaf J, Stevens J

European journal of clinical pharmacology, 2016 Oct; 72(11):1343-1352

View publication
Pharmacokinetics and pharmacodynamics of multiple doses of BG00010, a neurotrophic factor with anti-hyperalgesic effects, in patients with sciatica.

Okkerse P, Hay JL, Versage E, Tang Y, Galluppi G, Ravina B, Verma A, Williams L, Aycardi E, Groeneveld GJ

British journal of clinical pharmacology, 2016 Jun; 82(1):108-17

View publication
Vaccination during myeloid cell depletion by cancer chemotherapy fosters robust T cell responses.

Welters MJ, van der Sluis TC, van Meir H, Loof NM, van Ham VJ, van Duikeren S, Santegoets SJ, Arens R, de Kam ML, Cohen AF, van Poelgeest MI, Kenter GG, Kroep JR, Burggraaf J, Melief CJ, van der Burg SH

Science translational medicine, 2016 Apr; 8(334):334ra52

View publication

«
1
2
3
»